U.S. Medical Equipment Stock News

Wondering whether Nuvation Bio at around US$5.04 is offering genuine value or just riding on excitement? This article breaks down what the current share price may be implying about the business. The stock has returned 4.8% over the last 7 days and 17.8% over the last 30 days, while year to date it is down 41.3% and the 1 year return sits at 136.6%, with a 3 year return of 217.0% and a 5 year return of 56.5%. Recent price action has come alongside ongoing interest in the company’s drug...

Tri Pointe Homes amended its credit agreement to address lender terms related to its pending merger with Sumitomo Forestry. The amendment updates change in control provisions that could have affected the transaction. This move represents another formal step toward closing the merger between Tri Pointe Homes and Sumitomo Forestry. For investors watching NYSE:TPH, the amended credit agreement comes as the stock trades at $46.89 and has logged a 48.5% return year to date and 51.9% over the...

If you are wondering whether Atmos Energy at around US$187.81 is still reasonably priced or already baking in a lot of optimism, the valuation picture is worth a closer look. The stock has returned 3.4% over the last 30 days and 10.9% year to date, while the 1 year and 5 year returns sit at 20.2% and 108.2% respectively, which may have shifted how the market views its risk and reward balance. Recent coverage has focused on Atmos Energy as a regulated gas utility with ongoing investment in...

Blackstone (BX) has just laid out its latest scorecard, with Q4 2025 revenue at US$4.2b and basic EPS of US$1.30 setting the stage for how investors approach the Q1 2026 update. Over recent quarters, revenue has shifted from US$3.2b in Q1 2025 to US$4.2b in Q4 2025, while basic EPS has ranged from US$0.80 to US$1.30 across that period, and trailing 12 month net income reached US$3.0b on revenue of US$14.2b. With a trailing net profit margin of 21.2% and forecasts indicating faster revenue...

Union Pacific (UNP) opened Q1 2026 earnings season with Q4 2025 revenue of US$6.1 billion and basic EPS of US$3.12, capping a trailing twelve month period in which EPS reached US$12.00 on revenue of US$24.5 billion and earnings grew 5.8% year over year. Over recent quarters, the company has seen revenue move in a tight range between US$6.0 billion and US$6.2 billion while quarterly basic EPS tracked between US$2.71 and US$3.16. This gives a clear view of how the earnings line has behaved...

Nano-X Imaging’s April 2026 update showed fourth-quarter 2025 sales rising to US$3.72 million while net loss widened to US$33.37 million, including a US$17.53 million impairment, alongside full-year 2025 losses and the appointment of incoming CFO Guy Nathanzon after Ran Daniel’s planned departure. At the same time, a new clinical collaboration with Meir Medical Center to further validate the Nanox.ARC system highlights management’s focus on strengthening the technology’s real-world...

Cathay General Bancorp (CATY) opened 2026 with Q1 revenue of US$196.6 million and basic EPS of US$1.30, alongside net income of US$86.9 million. This followed a year in which trailing twelve month revenue reached US$769.6 million and EPS came in at US$4.86. Over the past year, revenue has moved from US$691.3 million to US$769.6 million on a trailing basis, while TTM EPS increased from US$3.97 to US$4.86. This gives investors a clearer view of how the latest quarter fits within a steadily...

Sprinklr (NYSE:CXM) has launched its Spring 2026 Release, introducing advanced AI-driven features for its customer experience platform. The release adds autonomous agent evaluation tools designed to assess and monitor AI performance in customer service. Sprinklr also announced a new alliance with CreatorIQ to integrate creator intelligence with its unified social media management capabilities. Sprinklr enters this product release cycle with its shares at $4.84 and a value score of 2,...

ZORYVE (roflumilast) cream has received a strong, high certainty recommendation in the American Academy of Dermatology’s new pediatric atopic dermatitis guidelines. This is the AAD’s first set of clinical practice guidelines focused on pediatric atopic dermatitis, giving the product formal visibility in a key treatment area. The endorsement supports ZORYVE’s role as an evidence backed option for long term use in children with atopic dermatitis. For Arcutis Biotherapeutics (NasdaqGS:ARQT),...

Heartland Express (HTLD) opened 2026 with Q1 results that extend a run of soft profitability, capped by trailing 12 month revenue of US$805.7 million and a basic EPS loss of US$0.67 tied to a net loss of US$52.5 million. Over the past six reported quarters, quarterly revenue has ranged from US$179.4 million to US$259.9 million, while basic EPS has moved between a loss of US$0.02 and a loss of US$0.25. This sets up a story where investors are weighing ongoing losses against forecasts that...

Martin Midstream Partners (MMLP) opened 2026 with Q1 results that keep the focus squarely on profitability, as the latest trailing 12 month figures show total revenue of US$716.1 million and a loss of US$14.4 million, or basic EPS of US$0.37. Over recent quarters, the partnership has seen quarterly revenue range from US$168.7 million to US$192.5 million, while basic EPS has moved between a profit of US$0.09 and losses of up to US$0.21. This sets up an earnings release where investors are...

Popular (BPOP) has just posted another solid quarter, with Q4 2025 revenue of US$751.8 million and basic EPS of US$3.54, setting the tone as investors look at the new Q1 2026 reporting period. The bank has seen quarterly revenue move from US$689.4 million in Q4 2024 to US$751.8 million in Q4 2025, while basic EPS over that same stretch climbed from US$2.51 to US$3.54, giving you a clear sense of how the income line has scaled alongside the top line. Taken together with an improved net profit...

Katahdin Bankshares (KTHN) has just put another quarter on the board, with Q4 2025 revenue of US$11.9 million and basic EPS of US$0.99 setting the tone after a year in which trailing net income reached US$10.7 million on revenue of US$44.3 million. Over recent periods the company has seen revenue move from US$9.5 million and EPS of roughly US$0.56 in Q4 2024 to US$11.9 million and US$0.99 respectively in Q4 2025. Trailing basic EPS for the last reported twelve months reached about US$3.37...

American Riviera Bancorp (ARBV) opened 2026 with Q1 results that build on a solid finish to last year, with Q4 2025 revenue at about US$14.4 million and basic EPS of roughly US$0.80, while trailing twelve month revenue stood at about US$50.4 million and EPS at roughly US$2.18. Over recent quarters, revenue has moved from about US$10.7 million in Q4 2024 to US$14.4 million in Q4 2025, and basic EPS has shifted from roughly US$0.35 to US$0.80. This sets up a story where higher net income and...

Medpace Holdings (MEDP) has followed up its recent run of strong results with Q4 2025 revenue of US$708.5 million and basic EPS of US$4.78, backing that up with trailing 12 month revenue of about US$2.5 billion and EPS of US$15.64. Over recent quarters the company has seen revenue move from US$533.3 million in Q3 2024 to US$708.5 million in Q4 2025, while quarterly basic EPS has ranged from US$3.11 to US$4.78 across the same stretch. With trailing net profit margins at 17.8% versus 19.2% the...

Mesabi Trust (MSB) has put fresh FY 2026 numbers on the table, with third quarter revenue of US$3.6 million, basic EPS of US$0.21 and net income of US$2.8 million. The trust has seen quarterly revenue move between US$4.7 million and US$6.9 million and EPS range from US$0.28 to US$0.46 over the past year of reported periods, alongside net income between US$3.6 million and US$6.1 million. This sets a clear context for the latest print. With a trailing net margin of 82.8% and earnings quality...

Farmers & Merchants Bancorp (FMAO) has put fresh numbers on the board, with Q4 2025 revenue of about US$31.9 million and basic EPS of US$0.70, supported by net income of US$9.7 million as the latest marker ahead of its Q1 2026 reporting period. The business has seen revenue move from US$26.6 million and EPS of US$0.59 in Q4 2024 to US$31.9 million and EPS of US$0.70 in Q4 2025. Trailing 12 month earnings growth of 29.4% and a 27.6% net margin frame a profitability profile that many investors...

Southern Missouri Bancorp (SMBC) opened Q3 2026 with Q2 results that put revenue and earnings in clear focus, reporting total revenue of US$48.0 million and basic EPS of US$1.62 on net income of US$18.1 million. The company has seen revenue move from US$41.7 million with EPS of US$1.10 in Q1 2025 to US$45.1 million and EPS of US$1.40 in Q4 2025, then to US$48.0 million and EPS of US$1.62 in Q2 2026. This latest report can be viewed as part of a steady earnings story that investors can now...

Thermo Fisher Scientific (TMO) has just put fresh numbers on the table, with Q4 2025 revenue of US$12.2b and basic EPS of US$5.22 setting the tone against a trailing twelve month EPS of US$17.78 on revenue of US$44.6b, alongside net income of US$6.7b. The company has seen quarterly revenue move from US$10.6b in Q3 2024 to US$12.2b in Q4 2025, while basic EPS over the same period went from US$4.27 to US$5.22. This gives investors a clear read on top line scale and earnings power as they assess...

Kearny Financial (KRNY) has just reported Q3 2026 results with quarterly revenue in the low US$40 million range and basic EPS of about US$0.15, set against a trailing twelve month EPS of US$0.52 that reflects the shift back into profitability. Over recent periods, revenue has moved from US$36.96 million in Q1 2025 to US$42.97 million in Q2 2026, while quarterly EPS has stepped from roughly US$0.10 to just over US$0.15. This gives investors a clearer read on how earnings now sit relative to...

First Bancorp (FBNC) opened 2026 with Q1 results that put the focus squarely on the income statement, reporting total revenue of US$119.2 million and basic EPS of US$1.13, backed by trailing twelve month revenue of US$393.3 million and EPS of US$2.93. Over recent periods the company has seen quarterly revenue move from US$65.2 million in Q4 2024 to US$104.7 million in Q1 2025, US$108.8 million in Q2, US$86.2 million in Q3 and US$79.2 million in Q4, while EPS shifted from US$0.09 to US$0.88,...

Dover (DOV) kicked off Q1 2026 against a backdrop of recent quarterly revenue between US$1.87 billion and US$2.10 billion and basic EPS ranging from US$1.74 to US$2.21 through 2025, with trailing 12 month revenue at about US$8.09 billion and EPS at US$8.01. Over that same trailing period, revenue has stayed in a tight band around US$7.72 billion to US$8.09 billion, while EPS moved between US$7.55 and US$8.01. This provides a clear sense of how top line and per share earnings have been...

CSX (CSX) has just opened its 2026 reporting year with investors still focused on the recent Q4 2025 numbers, where revenue came in at US$3.5b and basic EPS was US$0.39, setting the reference point for how Q1 performance will be judged. Over the past few quarters, revenue has held in a tight band around US$3.4b to US$3.6b, while basic EPS moved between US$0.34 and US$0.44, giving a clear read on how small shifts in volumes and pricing flow through to earnings. With trailing net margins at...

QCR Holdings (QCRH) just wrapped up Q1 2026 with recent quarterly revenue running around US$101.5 million and basic EPS of about US$2.13, backed by trailing twelve month revenue of roughly US$351.5 million and EPS of US$7.54 that has been associated with an 11.7% earnings growth rate over the past year. Over recent periods, the company has seen revenue move from US$330.2 million and EPS of US$6.77 on a trailing basis in Q4 2024 to US$351.5 million and EPS of US$7.54 by Q4 2025, supported by a...